atlernative ecarin clotting time - ucl namur€¦ · femoral neck fracture, accidental fall -->...
TRANSCRIPT
Ecarin Clotting Time
Ecarin = highly puridied metalloprotease isolated from the venom otEchis carinatus.
Generation of meizothrombin (Ecarin + prothrombin), insensitive to heparin. Able to transform fibrinogen into fibrin.
Ecarin Chromogenic Assay --> meizothrombin is measured using a specific chromogenic substrate.
Douxfils J, Muller F et al, Thomb Haemost 2012 May 2;107(5):985-97
Atlernative
Limitations of aPTT
No reflect of circulating concentrations of dabigatran
No demonstrated link with the bleeding risk
Influence of the reagents and instruments : we need more specific recommendations. More studies are needed.
Prolonged aPTT indicates a supratherapeutic concentration but should be interpreted with caution because of the anticoagulant effect could be underestimated.
A normal aPTT exclude probably an anticoagulant effect from dabigatran
Calibrations and controls are essential
Douxfils J, Muller F et al, Thomb Haemost 2012 May 2;107(5):985-97
Protocol
Results in the therapeutic range
«Result in the therapeutic range, defined on in vitro data»
Infratherapeutic results
«Result under the therapeutic range, defined on in vitro data. It is important to check drug interactions and compliance».
Supratherapeutic results
«Result above the therapeutic range, define on in vitro data. It is imporant to check drug interactions and renal/liver functions.
Dose individualisation
According to european guidelines
Rivaroxaban (Xarelto®)
In practice... Rivaroxaban
PT for the monitoring of Rivaroxaban as a screening test.
Chromogenic anti-Xa tests (i.e. Biophen DiXaI or Liquid Anti-Xa)
Rivaroxaban + FXaexcess --> Riva-FXa + FXaresidual
FXaresidual + chromogenic molecule --> 405 nm
Result in ng/mL of rivaroxaban
Limitations of PT
No reflect of the rivaroxaban’s circulating concentration
No demonstrated link with the bleeding risk
Reagents and instruments influence : more studies need to be done to suggest more specific recommendations
INR is not valid !
A normal PT (with sensitive reageant) excludes a significative anticoagulant effect from rivaroxaban
Calibrations and controls are essentials
Protocol
Results in the therapeutic range
«Result in the therapeutic range, defined on in vitro data»
Infratherapeutic results
«Result under the therapeutic range, defined on in vitro data. It is important to check drug interactions and compliance».
Supratherapeutic results
«Result above the therapeutic range, define on in vitro data. It is imporant to check drug interactions and renal/liver functions.
Clinical cases
N° 1 (23/01/1951), (M)
AF
Prostate cancer
COPD III
Pancreatitis 2007
Pulmonary embolism 2009
Peptic ulcer
Atheromatosis
Thrombophilia : FVIII ++ and heterozygous for prothrombin mutation
Renal fuction : Creat. 1,19 mg/dL, CG 59 mL/minLiver function : OK (GGT 115 UI/L (15-73))
N° 1, monitoring Xarelto 15 mg/d
27/07/2012
0 min : 71,03 ng/mL --> therapeutical trough
120 min : 399,13 ng/mL --> supra-therapeutic
180 min : 449,84 ng/mL --> supra-therapeutic
For 20 mg/d
5 32 155 177 290 409Ctrough Cmax
Douxfils J et al, Thromb. Res. 2012, Sep.21
N° 1 - Traitements
Xarelto 15 mg
Cordarone
SimvastatineEsomeprazole
Spiriva, InuvairDurogesic
Rivotril drops
Zestril
Duovent
MontelukastMedrol
Oxygenotherapy
CYP450 and P-gp ?
N° 1 - Traitements
Xarelto 15 mg
Cordarone Simvastatine Esomeprazole
Spiriva, InuvairDurogesic
Rivotril drops Zestril
Duovent
MontelukastMedrol
CYP450 and P-gp ?
Substrate CYP3A4Inhibitor
CYP2C9, 3A4, 2D6, P-gp
Substrate CYP3A4Inhibitor P-gp Substrate CYP3A4
Inhibitor CYP2C19
Inhibitor CYP2C8
Substrate CYP3A4 et P-gp
Substrate CYP3A4
Durg interactions
Amiodarone --> Flécaïnide ? (CYP2D6). Taken for AF post-embolia. Paroxystic, re-evaluation ?
Simvastatine : strong substrate of CYP3A4 (competition ?), principal metabolic pathway --> Pravastatine ?
...
In case of overdose, check the drug interactions ! Often, polymedicated patients !
Substrate CYP3A4Inhibitor
CYP2C9, 3A4, 2D6, P-gp
Cytochromes Cytochromes P450P450
- Hemoproteins particularly implicated in Xenobiotics metabolism.- Localisation in the liver, but also in the gastrointestinal tract.
- Substrates- Inducers- Inhibitors
Major durgs interactions’ mechanism
Rejection in the GI tract
P- glycoprotein
SubstratesInducers + Inhibitors-
Rivaroxaban and DabigatranAbsorption
- Ciclosporine, Tacrolimus- Amiodarone- Simvastatine- Clarithromycin- Ketoconazole- Phenytoïn- Ritonavir
- Ciclosporine- Amiodarone- Verapamil- Ketoconazole- Ritonavir- Tamoxifène- Grapefruit juice
- Rifampicine- Phenytoïn- Dexaméthasone- Millepertuis
«Multi-Drug Resistance Pump»
Common drug interactions
Rifampicine
Ketoconazole
Verapamil
Clarithromycin (particularly in patients with renal impairment)
Millepertuis (Hypercium perforatum)
Carbamazepin or phenytoïn
Ciclosporine, Tacrolimus
Before NOACs administration, drug
anamnesis is mandatory !
N°2, 23/07/1957 (F)
1m61, 108 kg (BMI = 42) after diet !
AF
Renal and liver functions : ok
No response to VKA !
acenocoumarol (Sintrom) : to 15 mg/d with INR = 1
warfarine (Marevan): to 5 mg/d with INR = 1
phenprocoumone (Marcoumar)
«Resistance» to clonazepam, hydroxizine and zolpidem
Stroke on AF, supra-ventricular tachycardia, ...
By pass !
N°2, 23/07/1957 (F)
Rivaroxaban 20 mg (no dabigatran because of the extreme weight)
Switch Clexane --> Rivaroxaban
Last Clexane intake : 17 august, 9h00
First dose of Rivaroxaban : 18 august, 10h05
Complete PK J0, J6 and J56 : 0min, 30min, 1h, 1h30, 2h, 3h, 4h et 6h
Genotyping : CYP3A4, CYP2C9, VKORC1, ...
VKA metabolism
AVK
AVK
Cofactor γ-carboxylationAVK
CYP450 and anticoagulants
AcénocoumarolWarfarine
Rivaroxaban
Phenprocoumone
?
Other genes can be involved...
Genotyping ?
CYP2C9
CYP3A4CYP3A5
ABCB1
VKORC1
TaqMan, Luminex, Genechip, MLPA, Sequencing, ....
N°2, 23/07/1957 (F)
No detection of common mutations for CYP2C9 or VKORC1
! We only find what we are looking for ! Sequencing ?
CYP3A4*22 negative (Haufroid et al)
CYP3A5 positive ! (20% population) --> increase in CYP3A activity
Part in VKA resistance ?
African population is more resistant to VKA and CYP3A5 is more expressed... (--> ?)
PPAR-A, POR*28, ..., under investigation
Assay
PT values are not similar for the different plasmatic concentrations
Anti-Xa assays (chromogenics) give similar results
Cmax 2-4h after intake0 min, 30min, 1h, 1h30, 2h, 3h, 4h et 6h
N°3 : N.J, 17/02/1924 (F)
Femoral neck fracture, accidental fall --> 23/10/2012 in Mont-Godinne
Dabigatran 110 mg bd, AF
Last intake : 22/10 at 22h15
Renal function with CG : 34,8 mL/min
Coagulation assays 23/10 :
aPTT = 64,4 sec (26,0-38,0), TT > 120 sec
N°3 : N.J, 17/02/1924 (F)
Recommandations : with Clcreat 30-50 mL/min --> stop for 4 days before surgery (26/10 ?)
monitoring 25/10 morning + switch to Clexane 40 2x/d ?
Monitoring dabigatran 25/10 --> 0 ng/mL (Hemoclot), aPTT 29,9 sec, TT 23,4 sec.
Surgery the 25/10
NOACs and renal impairment
Dabigatran : ~80% renal elimination.
Rivaroxaban : ~50% renal elimination.
Renal impairment ?
Mild : no recommendation
Moderate (ClCr 30-49 ml/min) --> use with caution, clinical surveillance (bleeding, ...).
Severe (ClCr 15-29 ml/min) : caution ! ... Not recommanded in patient with ClCr < 15 mL/min, risk of bleeding.
European medicines agency
ie : Dabigatran
Cas n°3, 30 mai 1972, (M)
Thrombose de la veine saphène droite en 1997 (à 25 ans) --> Fraxiparine.
Bilan thrombophilie (FV Leiden muté, facteur VIII élevé (180%) (et IX)), antécédents de thromboses familiales.
Enormes difficultés à être mis sous AVK... 2002, embolie pulmonaire. Arrêt AVK --> Fraxiparine
Mis sous HBPM pendant quelques années, mais lui est pénible.
Mise sous Pradaxa au Luxembourg (mutuelle luxembourgeoise), mi-2011.
23/02/2012 : depuis 48h, cordon induré sensible au niveau de la face interne de la jambe droite, notion de voyage en avion en Italie --> thrombophlébite de la veine saphène interne droite. Volumineux caillot visible à l’échographie --> Fraxodi 1 ml 1x/jour.
Pradaxa 110 mg 2co en une prise.
23/02/2012 : Monitoring, délais entre prise et prélèvement : 9h
TCA Synthasil : 47,4 sec (26,0 - 38,0)
TT > 120 sec
Hemoclot Thrombin inhibitor 80 ng/mL. Patient dans la zone thérapeutique*.
Bilan hépatique, rénal --> OK ! Pas de co-médication particulière.
Cas n°3, 30 mai 1972, (M)
* Douxfils J et al, Thrombosis and Haemostasis 107.5/2012
06/04/2012 : sous Pradaxa depuis 1 an, 2x110 mg 1x/jour. Report par le patient de l’oubli d’une dose, et survenue d’un début de phlébite... Après confirmation, passage au Xarelto (a décidé qu’il ne prendrait plus de Pradaxa)
23/10/2012 : oubli de prendre le médicament, survenue douleurs jambes et perturbations de la vue (30 min) --> rentré dans l’ordre à la prise de Xarelto.
Traitement à domicile : Xarelto 20 mg/jourLabo : Rivaroxaban, 20 mg
19/07/2012 : 0 min : 0 ng/mL120 min : 190 ng/mL180 min : 166 ng/mL
23/10/2012 : 0 min : 31 ng/mL120 min : 203 ng/mL180 i 210 / L
Cas n°3, 30 mai 1972, (M)
5 32 155 177 290 409
Cvallée et Cmax dans les intervalles thérapeutiques
Conclusion cas n°3
Manque de compliance ? Le Sintrom n’était pas gérable chez ce patient. «N’en fait qu’à sa tête...»
Fraxiparine OK, mais pénible pour lui.
Monitoring Pradaxa ok, mais pas évident d’évaluer la compliance en faisant du monitoring (non rétrospectif). Aléas dans les prises, épisodes thrombotiques, le patient refuse de continuer à prendre le médicament.
Passage au Xarelto, mieux supporté.
Conclusion
A biological follow-up of NOACs is indicated in some situations
In case of infra- or supra-therapeutic concentration, be careful to renal function, liver function, drug interactions and compliance.
Knowledge for the laboratory of the impact of NOACs on routine coagulation assays !
Physician-Biologist dialogue is of utmost importance !
All this has to be well orchestrated !
Website NTHC (Namur Thrombosis and Hemostasis Center)
Google --> NTHC (first website*)
Practical Guide Rivaroxaban
Practical Guide Dabigatran
*http://www.uclmontgodinne.be/gorganimedical.php?action=servicedetail&serviceid=143
Thanks to...
Ph. J. Douxfils, Pr. JM. Dogné
Ph. AS Larock, Ph G.Remy, Pr. A. Spinewine
Dr V. Mathieux, Pr. F. Mullier, Pr. B. Chatelain, Pr C. Chatelain
Pr. V. Haufroid